Acquisition of regulatory function by human CD8+ T cells treated with anti-CD3 antibody requires TNF

European Journal of Immunology

Volumn 40, Issue 10, 2010, Pages 2891-2901

  Ablamunits, Vitaly ^a   Bisikirska, Brygida ^b   Herold, Kevan C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Anti CD3 mAb; CD8+ Treg; TNF

Indexed keywords

CD3 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TEPLIZUMAB; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHILD; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD3; CD8-POSITIVE T-LYMPHOCYTES; CHILD; DIABETES MELLITUS, TYPE 1; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-10; MUROMONAB-CD3; NF-KAPPA B; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77957147196     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201040485     Document Type: Article

References (47)

1. Shou, L., Schwartz, S. A. and Good, R. A., Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors. J. Exp. Med. 1976. 143: 1100-1110.
2. Sampson, D., Kauffman, H. M., Jr., Grotelueschen, C. and Metzig, J., Suppressor activity of the human spleen and thymus. Surgery 1976. 79: 393-397.
3. Hubert, C., Delespesse, G. and Govaerts, A., Concanavalin A-activated suppressor cells in normal human peripheral blood lymphocytes. Clin. Exp. Immunol. 1976. 26: 95-98.
4. Walker, M. R., Kasprowicz, D. J., Gersuk, V. H., Benard, A., Van Landeghen, M., Buckner, J. H. and Ziegler, S. F., Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25-T cells. J. Clin. Invest. 2003. 112: 1437-1443.
5. Bettelli, E., Oukka, M. and Kuchroo, V. K., T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 2007. 8: 345-350.
6. Bach, J. F., Regulatory T cells under scrutiny. Nat. Rev. Immunol. 2003. 3: 189-198.
7. Bar-Or, A., Calabresi, P. A., Arnold, D., Markowitz, C., Shafer, S., Kasper, L. H., Waubant, E. et al., Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann. Neurol. 2008. 63: 395-400.
8. Billerbeck, E. and Thimme, R., CD8+ regulatory T cells in persistent human viral infections. Hum. Immunol. 2008. 69: 771-775.
9. Suciu-Foca, N., Manavalan, J. S. and Cortesini, R., Generation and function of antigen-specific suppressor and regulatory T cells. Transpl. Immunol. 2003. 11: 235-244.
10. Jiang, H. and Chess, L., The specific regulation of immune responses by CD8+ T cells restricted by the MHC class Ib molecule, Qa-1. Annu. Rev. Immunol. 2000. 18: 185-216.
11. Joosten, S. A., van Meijgaarden, K. E., Savage, N. D., de Boer, T., Triebel, F., van der Wal, A., de Heer, E. et al., Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc. Natl. Acad. Sci. USA 2007. 104: 8029-8034.
12. Panoutsakopoulou, V., Huster, K. M., McCarty, N., Feinberg, E., Wang, R., Wucherpfennig, K. W. and Cantor, H., Suppression of autoimmune disease after vaccination with autoreactive T cells that express Qa-1 peptide complexes. J. Clin. Invest. 2004. 113: 1218-1224.
13. Ablamunits, V., Bisikirska, B. C. and Herold, K. C., Human regulatory CD8 T cells. Ann. NY Acad. Sci. 2008. 1150: 234-238.
14. Kessel, A., Ammuri, H., Peri, R., Pavlotzky, E. R., Blank, M., Shoenfeld, Y. and Toubi, E., Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J. Immunol. 2007. 179: 5571-5575.
15. Ricciardelli, I., Lindley, K. J., Londei, M. and Quaratino, S., Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. Immunology 2008. 125: 178-183.
16. Rigby, M. R., Trexler, A. M., Pearson, T. C. and Larsen, C. P., CD28/CD154 blockade prevents autoimmune diabetes by inducing nondeletional tolerance after effector t-cell inhibition and regulatory T-cell expansion. Diabetes 2008. 57: 2672-2683.
17. Monti, P., Scirpoli, M., Maffi, P., Piemonti, L., Secchi, A., Bonifacio, E., Roncarolo, M. G. and Battaglia, M., Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP31 regulatory T-cells. Diabetes 2008. 57: 2341-2347.
18. Hering, B. J., Kandaswamy, R., Harmon, J. V., Ansite, J. D., Clemmings, S. M., Sakai, T., Paraskevas, S. et al., Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am. J. Transplant. 2004. 4: 390-401.
19. Herold, K. C., Gitelman, S. E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K. et al., A Single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005. 54: 1763-1769.
20. Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E. et al., Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 2002. 346: 1692-1698.
21. Glandt, M., Hagopian, W. and Herold, K. C., Treatment of type 1 diabetes with anti-CD3 monoclonal antibody. Rev. Endocr. Metab. Disord. 2003. 4: 361-368.
22. Bisikirska, B., Colgan, J., Luban, J., Bluestone, J. A. and Herold, K. C., TCR stimulation with modified anti-CD3 mAb expands CD8 T cell population and induces CD8CD25 Tregs. J. Clin. Invest. 2005. 115: 2904-2913.
23. Zhang, J., Medaer, R., Stinissen, P., Hafler, D. and Raus, J., MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 1993. 261: 1451-1454.
24. Correale, J. and Villa, A., Isolation and characterization of CD8+regulatory T cells in multiple sclerosis. J. Neuroimmunol. 2008. 195: 121-134.
25. Filaci, G., Fenoglio, D., Fravega, M., Ansaldo, G., Borgonovo, G., Traverso, P., Villaggio, B. et al., CD8+CD28-T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J. Immunol. 2007. 179: 4323-4334.
26. Battaglia, M. and Roncarolo, M. G., The role of cytokines (and not only) in inducing and expanding Tregulatory type 1 cells. Transplantation 2004. 77: S16-S18.
27. Levings, M. K., Gregori, S., Tresoldi, E., Cazzaniga, S., Bonini, C. and Roncarolo, M. G., Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+Tr cells. Blood 2005. 105: 1162-1169.
28. Wegener, E. and Krappmann, D., Dynamic protein complexes regulate NF-kappaB signaling. Handb Exp. Pharmacol. 2008: 237-259.
29. Cavallini, L., Francesconi, M. A., Zoccarato, F. and Alexandre, A., Involvement of nuclear factor-kappa B (NF-kappaB) activation in mitogen-induced lymphocyte proliferation: inhibitory effects of lymphoproliferation by salicylates acting as NF-kappaB inhibitors. Biochem. Pharmacol. 2001. 62: 141-147.
30. Wahl, C., Liptay, S., Adler, G. and Schmid, R. M., Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J. Clin. Invest. 1998. 101: 1163-1174.
31. Weber, C. K., Liptay, S., Wirth, T., Adler, G. and Schmid, R. M., Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 2000. 119: 1209-1218.
32. Pierce, J. W., Schoenleber, R., Jesmok, G., Best, J., Moore, S. A., Collins, T. and Gerritsen, M. E., Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 1997. 272: 21096-21103.
33. Yabe, T., Wilson, D. and Schwartz, J. P., NFkappaB activation is required for the neuroprotective effects of pigment epithelium-derived factor (PEDF) on cerebellar granule neurons. J. Biol. Chem. 2001. 276: 43313-43319.
34. Belghith, M., Bluestone, J. A., Barriot, S., Megret, J., Bach, J. F. and Chatenoud, L., TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 2003. 9: 1202-1208.
35. Siegmund, K., Ruckert, B., Ouaked, N., Burgler, S., Speiser, A., Akdis, C. A. and Schmidt-Weber, C. B., Unique phenotype of human tonsillar and in vitro-induced FOXP3+CD8+T cells. J. Immunol. 2009. 182: 2124-2130.
36. Sarantopoulos, S., Lu, L. and Cantor, H., Qa-1 restriction of CD81 suppressor T cells. J. Clin. Invest. 2004. 114: 1218-1221.
37. Ware, R., Jiang, H., Braunstein, N., Kent, J., Wiener, E., Pernis, B. and Chess, L., Human CD81 T lymphocyte clones specific for T cell receptor V beta families expressed on autologous CD4+ T cells. Immunity 1995. 2: 177-184.
38. Alleva, D. G., Crowe, P. D., Jin, L., Kwok, W. W., Ling, N., Gottschalk, M., Conlon, P. J. et al., A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J. Clin. Invest. 2001. 107: 173-180.
39. Chang, C. C., Ciubotariu, R., Manavalan, J. S., Yuan, J., Colovai, A. I., Piazza, F., Lederman, S. et al., Tolerization of dendritic cells by TS cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat. Immunol. 2002. 3: 215-217.
40. Chen, B., Kapturczak, M. H., Joseph, R., George, J. F., Campbell-Thompson, M., Wasserfall, C. H., Atkinson, M. A. et al., Adeno-associated viral vector-mediated interleukin-10 prolongs allograft survival in a rat kidney transplantation model. Am. J. Transplant. 2007. 7: 1112-1120.
41. Chen, X., Subleski, J. J., Hamano, R., Howard, O. M., Wiltrout, R. H. and Oppenheim, J. J., Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+regulatory T cells in human peripheral blood. Eur. J. Immunol. 2010. 40: 1099-1106.
42. Chen, X., Baumel, M., Mannel, D. N., Howard, O. M. and Oppenheim, J. J., Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+T regulatory cells. J. Immunol. 2007. 179: 154-161.
43. Chen, X., Subleski, J. J., Kopf, H., Howard, O. M., Mannel, D. N. and Oppenheim, J. J., Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP31T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J. Immunol. 2008. 180: 6467-6471.
44. Chen, X. and Oppenheim, J. J., TNF-alpha: an activator of CD4+FoxP3+ TNFR2+regulatory T cells. Curr. Dir. Autoimmun. 2010. 11: 119-134.
45. Rauert, H., Wicovsky, A., Muller, N., Siegmund, D., Spindler, V., Waschke, J., Kneitz, C. and Wajant, H., Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2). J. Biol. Chem. 2010. 285: 7394-7404.
46. Ferran, C., Bach, J. F. and Chatenoud, L., In vivo T cell activation properties of anti-T cell monoclonal antibodies. Exp. Nephrol. 1993. 1: 83-89.
47. Xu, D., Alegre, M. L., Varga, S. S., Rothermel, A. L., Collins, A. M., Pulito, V. L., Hanna, L. S. et al., In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell. Immunol. 2000. 200: 16-26.